Header Logo

Connection

HASHEM EL-SERAG to Esophageal Neoplasms

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Esophageal Neoplasms.
HASHEM EL-SERAG
Connection Strength
12.151
Esophageal Neoplasms
  1. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.645
  2. Why Has Screening and Surveillance for Barrett's Esophagus Fallen Short in Stemming the Rising Incidence of Esophageal Adenocarcinoma? Am J Gastroenterol. 2023 04 01; 118(4):590-592.
    View in: PubMed
    Score: 0.548
  3. Limits of the AGA Practice Update for Barrett's Esophagus Screening: A Proposal for Electronic Health Record-Adaptable Risk Models. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1963-1964.
    View in: PubMed
    Score: 0.537
  4. Development and Validation of the Houston-BEST, a Barrett's Esophagus Risk Prediction Model Adaptable to Electronic Health Records. Clin Gastroenterol Hepatol. 2023 08; 21(9):2424-2426.e0.
    View in: PubMed
    Score: 0.535
  5. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.513
  6. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
    View in: PubMed
    Score: 0.472
  7. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.367
  8. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.366
  9. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut. 2016 08; 65(8):1252-60.
    View in: PubMed
    Score: 0.330
  10. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.328
  11. Esophageal carcinoma. N Engl J Med. 2015 04 09; 372(15):1472-3.
    View in: PubMed
    Score: 0.321
  12. Esophageal carcinoma. N Engl J Med. 2014 Dec 25; 371(26):2499-509.
    View in: PubMed
    Score: 0.315
  13. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.311
  14. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.305
  15. Decision aids for shared decision-making in Barrett's esophagus surveillance. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):91-3.
    View in: PubMed
    Score: 0.302
  16. Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disorder. JAMA Intern Med. 2014 Mar; 174(3):462-5.
    View in: PubMed
    Score: 0.298
  17. Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next? Am J Gastroenterol. 2014 Feb; 109(2):178-82.
    View in: PubMed
    Score: 0.293
  18. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
    View in: PubMed
    Score: 0.291
  19. Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Serv Res. 2012 Aug 28; 12:288.
    View in: PubMed
    Score: 0.268
  20. Expression of androgen receptors in Barrett esophagus. J Clin Gastroenterol. 2012 Mar; 46(3):251-2.
    View in: PubMed
    Score: 0.259
  21. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006). Scand J Gastroenterol. 2011 May; 46(5):597-602.
    View in: PubMed
    Score: 0.240
  22. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci. 2010 Dec; 55(12):3404-7.
    View in: PubMed
    Score: 0.227
  23. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun; 138(7):2260-6.
    View in: PubMed
    Score: 0.225
  24. Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2009 Apr; 136(4):1155-7.
    View in: PubMed
    Score: 0.210
  25. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus. 2009; 22(7):571-87.
    View in: PubMed
    Score: 0.210
  26. Barrett's esophagus-associated genetic loci in African Americans: a case-control study using the All of Us Research Program. Eur J Gastroenterol Hepatol. 2026 06 01; 38(6):684-690.
    View in: PubMed
    Score: 0.170
  27. Fundoplication and the risk of esophageal cancer in gastroesophageal reflux disease: a Veterans Affairs cohort study. Am J Gastroenterol. 2005 May; 100(5):1002-8.
    View in: PubMed
    Score: 0.161
  28. High Risk of Persistence and Risk of Dysplasia After Diagnosis of Ultrashort Barrett's Esophagus. Am J Gastroenterol. 2025 Nov 01; 120(11):2520-2528.
    View in: PubMed
    Score: 0.160
  29. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004 Oct; 99(10):1877-83.
    View in: PubMed
    Score: 0.155
  30. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003 Jul; 98(7):1627-33.
    View in: PubMed
    Score: 0.142
  31. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. J Gastroenterol. 2022 12; 57(12):942-951.
    View in: PubMed
    Score: 0.135
  32. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2002 Jun; 31(2):421-40, viii.
    View in: PubMed
    Score: 0.132
  33. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002 Mar; 50(3):368-72.
    View in: PubMed
    Score: 0.130
  34. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.122
  35. Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000 Nov 07; 133(9):747-8.
    View in: PubMed
    Score: 0.118
  36. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.115
  37. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.111
  38. Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol. 1999 Mar; 28(2):135-9.
    View in: PubMed
    Score: 0.105
  39. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.103
  40. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.101
  41. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.101
  42. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.100
  43. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.100
  44. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.100
  45. Endoscopic ablation of low-grade dysplasia in Barrett's?esophagus: Have all the boxes been checked for?us?to move on? Gastrointest Endosc. 2017 07; 86(1):130-132.
    View in: PubMed
    Score: 0.094
  46. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017 04; 75:41-46.
    View in: PubMed
    Score: 0.091
  47. Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer. 2017 04 01; 140(7):1693-1699.
    View in: PubMed
    Score: 0.091
  48. Opportunities for Preventing Esophageal Adenocarcinoma. Cancer Prev Res (Phila). 2016 Nov; 9(11):828-834.
    View in: PubMed
    Score: 0.089
  49. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.087
  50. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis. 2017 Jan; 13(1):28-34.
    View in: PubMed
    Score: 0.083
  51. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606.
    View in: PubMed
    Score: 0.082
  52. Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett's esophagus. Cancer Causes Control. 2013 May; 24(5):1005-14.
    View in: PubMed
    Score: 0.069
  53. Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology. 2009 Sep; 137(3):763-5.
    View in: PubMed
    Score: 0.054
  54. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1299-304.
    View in: PubMed
    Score: 0.054
  55. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008 Sep; 53(9):2307-12.
    View in: PubMed
    Score: 0.050
  56. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008 Mar; 67(3):394-8.
    View in: PubMed
    Score: 0.048
  57. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 02; 143(3):199-211.
    View in: PubMed
    Score: 0.041
  58. Obesity and disease of the esophagus and colon. Gastroenterol Clin North Am. 2005 Mar; 34(1):63-82.
    View in: PubMed
    Score: 0.040
  59. Barrett's esophagus, hiatal hernia, and logistic regression analysis. Am J Gastroenterol. 1999 Dec; 94(12):3395-6.
    View in: PubMed
    Score: 0.028
  60. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998 Sep; 43(3):327-33.
    View in: PubMed
    Score: 0.025
  61. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.022
  62. Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decision-making. Dis Esophagus. 2013 Sep-Oct; 26(7):682-9.
    View in: PubMed
    Score: 0.017
  63. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sci. 1998 May; 43(5):1001-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.